Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BYM338 in mechanically ventilated patients requiring prolonged ventilation
2013-002201-66Phase 2Terminated
- Sponsor
- Novartis
- Start
- Aug 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Ventilator-induced diaphragmatic dysfunction (VIDD), acute quadriplegic myopathy (CIM) and ventilator dependence (PMV) comparing BYM338 150 mg IV with Placebo IV (2 arms). Primary endpoint: Change in thigh muscle thickness at Day 14. Started Aug 2013; status: terminated.
02
Drugs
bimagrumab
03
Conditions
Ventilator-induced diaphragmatic dysfunction (VIDD)acute quadriplegic myopathy (CIM)ventilator dependence (PMV)
Beyond the preview
Go deeper on 2013-002201-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002201-66.